- Home
- ULY vs CANF Comparison
ULY vs CANF Comparison
Compare ULY & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ULY
- CANF
- Stock Information
- Founded
- ULY 2013
- CANF 1994
- Country
- ULY United States
- CANF Israel
- Employees
- ULY N/A
- CANF N/A
- Industry
- ULY
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- ULY
- CANF Health Care
- Exchange
- ULY Nasdaq
- CANF Nasdaq
- Market Cap
- ULY 14.8M
- CANF 14.4M
- IPO Year
- ULY N/A
- CANF N/A
- Fundamental
- Price
- ULY $0.65
- CANF $1.97
- Analyst Decision
- ULY Strong Buy
- CANF Strong Buy
- Analyst Count
- ULY 1
- CANF 2
- Target Price
- ULY $2.00
- CANF $14.00
- AVG Volume (30 Days)
- ULY 590.1K
- CANF 116.8K
- Earning Date
- ULY 11-12-2024
- CANF 11-15-2024
- Dividend Yield
- ULY N/A
- CANF N/A
- EPS Growth
- ULY N/A
- CANF N/A
- EPS
- ULY 7.76
- CANF N/A
- Revenue
- ULY $165,727,000.00
- CANF $667,000.00
- Revenue This Year
- ULY N/A
- CANF $356.93
- Revenue Next Year
- ULY $20.40
- CANF N/A
- P/E Ratio
- ULY $0.08
- CANF N/A
- Revenue Growth
- ULY N/A
- CANF N/A
- 52 Week Low
- ULY $0.64
- CANF $1.81
- 52 Week High
- ULY $12.00
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- ULY 27.44
- CANF 35.55
- Support Level
- ULY $0.65
- CANF $1.87
- Resistance Level
- ULY $0.72
- CANF $2.04
- Average True Range (ATR)
- ULY 0.08
- CANF 0.15
- MACD
- ULY -0.00
- CANF 0.00
- Stochastic Oscillator
- ULY 2.89
- CANF 18.18
About ULY Urgent.ly Inc.
Urgently Inc is a connected mobility assistance software platform, matching vehicle owners and operators with service professionals who deliver traditional roadside assistance, proactive maintenance and repair services. The traditional experience of a vehicle breakdown is often stressful and inconvenient, compounded by processes that lack transparency and lead to long wait times. Urgently offers an innovative alternative to this traditional experience, leveraging its digitally native software platform to match supply and demand in its network and deliver exceptional mobility assistance experiences at scale.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).